184 related articles for article (PubMed ID: 11487216)
1. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Pierantozzi M; Pietroiusti A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Frasca S; Galante A; Marciani MG; Stanzione P
Neurol Sci; 2001 Feb; 22(1):89-91. PubMed ID: 11487216
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial).
Lolekha P; Sriphanom T; Vilaichone RK
PLoS One; 2021; 16(5):e0251042. PubMed ID: 33945559
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
[TBL] [Abstract][Full Text] [Related]
5. Motor fluctuations and Helicobacter pylori in Parkinson's disease.
Rahne KE; Tagesson C; Nyholm D
J Neurol; 2013 Dec; 260(12):2974-80. PubMed ID: 24002418
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Pierantozzi M; Pietroiusti A; Brusa L; Galati S; Stefani A; Lunardi G; Fedele E; Sancesario G; Bernardi G; Bergamaschi A; Magrini A; Stanzione P; Galante A
Neurology; 2006 Jun; 66(12):1824-9. PubMed ID: 16801644
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori eradication for Parkinson's disease.
Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
[TBL] [Abstract][Full Text] [Related]
8. Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
Nyholm D; Hellström PM
J Parkinsons Dis; 2021; 11(1):61-69. PubMed ID: 33164946
[TBL] [Abstract][Full Text] [Related]
9. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
Lyte M
Med Hypotheses; 2010 May; 74(5):895-7. PubMed ID: 19962247
[TBL] [Abstract][Full Text] [Related]
10. [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].
Doi H; Sakakibara R; Kishi M; Tsuyuzaki Y; Tateno F; Hirai S
Rinsho Shinkeigaku; 2013; 53(11):1382-5. PubMed ID: 24291998
[TBL] [Abstract][Full Text] [Related]
11. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Fiddian-Green RG
Neurology; 2007 Mar; 68(13):1085; author reply 1085. PubMed ID: 17389325
[No Abstract] [Full Text] [Related]
13. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori infection is associated with worse severity of Parkinson's disease.
Tan AH; Mahadeva S; Marras C; Thalha AM; Kiew CK; Yeat CM; Ng SW; Ang SP; Chow SK; Loke MF; Vadivelu JS; Ibrahim N; Yong HS; Tan CT; Fox SH; Lang AE; Lim SY
Parkinsonism Relat Disord; 2015 Mar; 21(3):221-5. PubMed ID: 25560322
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
[TBL] [Abstract][Full Text] [Related]
17. The long-duration action of levodopa may be due to a postsynaptic effect.
Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Djaldetti R; Rosmarin V; Ziv I; Melamed E
Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
[TBL] [Abstract][Full Text] [Related]
19. Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.
Mahato K; Moon JM; Moonla C; Longardner K; Ghodsi H; Litvan I; Wang J
Angew Chem Int Ed Engl; 2024 Jul; 63(27):e202403583. PubMed ID: 38682251
[TBL] [Abstract][Full Text] [Related]
20. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
